| 0 (0%) | 12-05 09:28 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.23 | 1-year : | 2.42 |
| Resists | First : | 1.91 | Second : | 2.07 |
| Pivot price | 1.81 |
|||
| Supports | First : | 1.64 | Second : | 1.37 |
| MAs | MA(5) : | 1.86 |
MA(20) : | 1.79 |
| MA(100) : | 1.79 |
MA(250) : | 0 | |
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 25.2 |
D(3) : | 44.9 |
| RSI | RSI(14): 46.9 |
|||
| 52-week | High : | 2.71 | Low : | 1.32 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ IMMP ] has closed above bottom band by 41.4%. Bollinger Bands are 48.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 3 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 1.82 - 1.83 | 1.83 - 1.84 |
| Low: | 1.72 - 1.74 | 1.74 - 1.75 |
| Close: | 1.76 - 1.78 | 1.78 - 1.8 |
Wed, 03 Dec 2025
Immutep to Present Promising AIPAC-003 Trial Data at SABCS 2025 - TipRanks
Tue, 02 Dec 2025
Immutep (IMMP) to Present Promising Trial Data at 2025 Cancer Sy - GuruFocus
Tue, 02 Dec 2025
Immutep (NASDAQ: IMMP) picks 30 mg efti dose as AIPAC-003 meets FDA Project Optimus - Stock Titan
Fri, 28 Nov 2025
Prima BioMed (NASDAQ:IMMP) Share Price Passes Below 50-Day Moving Average - Time to Sell? - MarketBeat
Mon, 03 Nov 2025
Immutep (IMMP) Secures R&D Tax Incentive from French Government - GuruFocus
Mon, 20 Oct 2025
51.5% tumour hyalinization: Immutep's efti + pembrolizumab meets Phase II primary endpoint at ESMO - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 0 (M) |
| Shares Float | 147 (M) |
| Held by Insiders | 1.22e+009 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 4,340 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -6.288e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -2 % |
| Return on Assets (ttm) | 35.4 % |
| Return on Equity (ttm) | -22.7 % |
| Qtrly Rev. Growth | 5.04e+006 % |
| Gross Profit (p.s.) | 5.16 |
| Sales Per Share | -20.05 |
| EBITDA (p.s.) | -3.06359e+007 |
| Qtrly Earnings Growth | -0.4 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -62 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.09 |
| Price to Cash Flow | 32.75 |
| Dividend | 0 |
| Forward Dividend | 4.61e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|